

**REMARKS**

This amendment under 37 CFR 1.312 is being filed concurrently with payment of the issue fee.

Claims 1 and 39-46 (re-numbered as claims 1-9, respectively) were deemed allowable by the Examiner.


The amendment to the specification made herein requires no additional search or examination. Applicants respectfully submit that the amendment made to the specification is made only to assure that a previous amendment to the title is entered into the application. In the Response filed on March 31, 2005, the title was amended to recite "Biopolymer Markers Indicative of Type II Diabetes". However, the Notice of Allowance and Fee(s) Due mailed on May 24, 2006 recites the original title "Apolipoprotein Biopolymer Marker Indicative of Normal Human".

Accordingly, Applicants respectfully request that the amendment to the title is entered into the instant application prior to issuance as a patent.

**CONCLUSION**

Applicants respectfully request favorable consideration of the instant amendment followed with issuance of the above-referenced application as a US Patent.

Respectfully submitted,

  
\_\_\_\_\_  
Ferris H. Lander  
Registration # 43,377

McHale & Slavin, P.A.  
2855 PGA Boulevard  
Palm Beach Gardens, FL 33410  
(561) 625-6575 (Voice)  
(561) 625-6572 (Fax)

\\Ns2\SERVER\CLIENT FILES\2100-2199\2132 -Syn-X\2132\_000107 - Apolipoprotein Biopolymer  
Marker\Amendments\2132\_107\_312\_Amend\_kfdw.wpd